PubMed Health⌕ Search

PubMed · 9933869

ISO 14000: Origin, Structure, and Potential Barriers to Implementation.

Abstract

The ISO 14000 is likely to become the international standard for environmental management. At present, it is an evolving series of individual voluntary standards and guideline reference documents that provide business management with the structure for managing environmental impacts. These encompass environmental management systems, environmental audits, eco-labeling, environmental performance evaluations, life-cycle assessment, and environmental aspects in product standards. The authors present the rationale for the ISO 14000 and the steps in its evolution so far, as well as its present provisions and their implications and its position with regard to regulatory agencies. Particular attention is paid to the consequences of voluntary disclosure and correction of violations. Hanley & Belfus, Inc. Int J Occup Environ Health 1077-3525 2 2 1996 April/June Perspectives on Rural Environmental Health in Central Europe 125 134 EN Tomas Trnovec Burton C. Kross CIREH-Room 352, International Center, University of Iowa, Iowa City, IA 52242, USA. Emil Ginter Life expectancy is about five to seven years less in Central European countries than in comparable countries in Western Europe. Environmental and occupational health risk factors, along with the socioeconomic and political conditions that have prevailed in this region for the past 40 years, are suspected contributing factors to this condition. The initial impression among observers was that environmental pollution by industry was the primary source of contamination leading to human health effects. Current thinking by the authors recognizes that combinations of personal habits, local environmental emissions (home heating), and occupational risk factors are more likely to be influencing the health of this region, particularly in rural areas. A predictive model for standard mortality rates determined that only three potential risk factors were statistically significant: consumption of alcoholic beverages, consumption of citrus fruits, and consumption of cereals. Additional emphasis should be placed on defining risk factors in rural areas of Central Europe, and designing intervention strategies to address these factors.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

KM Casto, EP Ellisen, T Trnovec, BC Kross, E Ginter. 1996. ISO 14000: Origin, Structure, and Potential Barriers to Implementation.. https://doi.org/10.1179/oeh.1996.2.2.99

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗